In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

Antiviral Therapy

Volumn 15, Issue 8, 2010, Pages 1161-1169

  Dierynck, Inge ^a   De Meyer, Sandra ^a   Lathouwers, Erkki ^a   Abeele, Carline Vanden ^a   Van De Casteele, Tom ^a   Spinosa Guzman, Sabrina ^a   De Béthune, Marie Pierre ^a   Picchio, Gaston ^b  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR DISOPROXIL;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LOAD;

ADAMANTANE; ADULT; ANALYSIS OF VARIANCE; CARBAMATES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; NELFINAVIR; NEURAMINIDASE; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; PYRONES; SAQUINAVIR; SULFONAMIDES; VIRAL LOAD;

EID: 78651099588     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1697     Document Type: Article

References (45)

1. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008; 358:1590-1602.
2. Robertson DL, Anderson JP, Bradac JA, et al. HIV-1 nomenclature proposal. Science 2000; 288:55.
3. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-W23.
4. Holguín A, de Mulder M, Yebra G, et al. Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr HIV Res 2008; 6:327-334.
5. Yirrell DL, Shaw L, Campbell E, et al. HIV subtypes in Scotland, 2000-2006. Epidemiol Infect 2008; 136:1069-1075.
6. Achkar JM, Burda ST, Konings FA, et al. Infection with HIV type 1 group M non-B subtypes in individuals living in New York City. J Acquir Immune Defic Syndr 2004; 36:835-844.
7. Barin F, Courouce AM, Pillonel J, Buzelay L. Increasing diversity of HIV-1 M serotypes in French blood donors over a 10-year period (1985-1995). Retrovirus Study Group of the French Society of Blood Transfusion. AIDS 1997; 11:1503-1508.
8. Couturier E, Damond F, Roques P, et al. HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network. AIDS 2000; 14:289-296.
9. Fleury H, Recordson-Pinson P, Caumont A, et al. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res Hum Retroviruses 2003; 19:41-47.
10. Alvarez M, Garcia F, Martinez NM, et al. Introduction of HIV type 1 non-B subtypes into Eastern Andalusia through immigration. J Med Virol 2003; 70:10-13.
11. Pieniazek D, Rayfield M, Hu DJ, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. AIDS 2000; 14:1489-1495.
12. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003; 51:229-240.
13. Palma AC, Abecasis AB, Vercauteren J, et al. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. Infect Genet Evol 2010; 10:373-379.
14. Soares EA, Santos AF, Sousa TM, et al. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE 2007; 2:e730.
15. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-F5.
16. Grossman Z, Istomin V, Averbuch D, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004; 18:909-915.
17. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009; 12:11.
18. Montes B, Vergne L, Peeters M, et al. Comparison of drug resistance mutations and their interpretation in patients infected with non-B variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004; 35:329-336.
19. Grossman Z, Paxinos EE, Averbuch D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004; 48:2159-2165.
20. Gomes P, Diogo I, Goncalves MF, et al. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G. 9th Conference on Retroviruses and Opportunistic Infections. 24-28 February 2002; Seattle, WA, USA. Abstract 46.
21. Santos AF, Abecasis AB, Vandamme AM, Camacho RJ, Soares MA. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. J Antimicrob Chemother 2009; 63:593-599.
22. Soares EA, Santos AF, Gonzalez LM, et al. Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J Antimicrob Chemother 2009; 64:938-944.
23. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007; 81:10209-10219. (Pubitemid 47463296)
24. Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 2006; 19:594-606. (Pubitemid 44665467)
25. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321.
26. Arastéh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009; 14:859-864.
27. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled Phase III trial. Lancet 2007; 370:49-58.
28. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679-1688.
29. PREZISTA™ (darunavir) summary of product characteristics. (Updated August 2010. Accessed 22 November 2010.) Available from http://www.ema.europa. eu/docs/en-GB/document-library/EPAR---Product-Information/human/000707/ WC500041756.pdf
30. Tibotec Inc. PREZISTA™ (darunavir) prescribing information. (Updated April 2010. Accessed 22 November 2010.) Available from http://www.prezista.com/sites/default/files/pdf/us-package-insert.pdf
31. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
32. Surleraux DL, Tahri A, Verschueren WG, et al. Discovery and selection of TMC114, a next-generation HIV-1 protease inhibitor. J Med Chem 2005; 48:1813-1822.
33. Trost BM, Andersen NG. Utilization of molybdenumand palladium-catalyzed dynamic kinetic asymmetric transformations for the preparation of tertiary and quaternary stereogenic centers: a concise synthesis of tipranavir. J Am Chem Soc 2002; 124:14320-14321.
34. Los Alamos National Laboratory. HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005. (Updated 26 January 2010. Accessed 3 March 2010.) Available from http://www.hiv.lanl.gov/content/sequence/HIV/ COMPENDIUM/2005/partI/leitner.pdf
35. Buckheit RW, Swanstrom R. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res Hum Retroviruses 1991; 7:295-302.
36. Poveda E, de Mendoza C, Parkin N, et al. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008; 22:611-616. (Pubitemid 351674068)
37. Frater AJ, Beardall A, Ariyoshi K, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1 infected African patients. AIDS 2001; 15:1493-1502. (Pubitemid 32744596)
38. Bocket L, Cheret A, Deuffic-Burban S, et al. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 2005; 10:247-254. (Pubitemid 41151031)
39. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002; 186:617-625. (Pubitemid 34925533)
40. Lacerda HR, Medeiros LB, Cavalcanti AM, et al. Comparison of the epidemiology, profile of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodeficiency virus type 1. Mem Inst Oswaldo Cruz 2007; 102:693-699.
41. Easterbrook PJ, Smith M, Mullen J, et al. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 2010; 13:4.
42. Geretti AM, Harrison L, Green H, et al. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48:1296-1305.
43. Flandre P, Delaugerre C, Ghosn J, et al. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK trial randomized to ritonavir-boosted lopinavir alone. Antivir Ther 2009; 14:93-97.
44. Abecasis AB, Deforche K, Bacheler LT, et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02-AG. Antivir Ther 2006; 11:581-589. (Pubitemid 44277423)
45. Gonzalez LM, Brindeiro RM, Tarin M, et al. In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother 2003; 47:2817-2822.